Veracyte, headquartered in South San Francisco, develops diagnostic products for various cancers and employs 815 people. The company went public in 2013 and offers tests like Afirma and Decipher.
Veracyte (VCYT) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Veracyte's actual EPS was $0.06, beating the estimate of $0.12 per share, resulting in a 94.33% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
